Cargando…
Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells
BACKGROUND: Triple-negative breast cancer (TNBC) has aggressive progression with poor prognosis and ineffective treatments. Selumetinib is an allosteric, ATP-noncompetitive inhibitor of MEK1/2, which has benn known as effective antineoplastic drugs for several malignant tumors. We hypothesized that...
Autores principales: | Zhou, Yan, Lin, Shuchen, Tseng, Kuo-Fu, Han, Kun, Wang, Yaling, Gan, Zhi-hua, Min, Da-liu, Hu, Hai-yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073736/ https://www.ncbi.nlm.nih.gov/pubmed/27769200 http://dx.doi.org/10.1186/s12885-016-2773-4 |
Ejemplares similares
-
Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells
por: Bilir, Birdal, et al.
Publicado: (2013) -
A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
por: Eroglu, Z, et al.
Publicado: (2015) -
Identification of the Major Degradation Pathways of Selumetinib
por: Bouchema, Tahar Sif eddine, et al.
Publicado: (2022) -
Selumetinib produces a central core of apoptosis in breast cancer bone metastases in mice
por: Bosma, Nicholas A., et al.
Publicado: (2014) -
Adenosine Stimulate Proliferation and Migration in Triple Negative Breast Cancer Cells
por: Fernandez-Gallardo, Miriam, et al.
Publicado: (2016)